Tunisie Medicale [La]. 2015; 93 (3): 123-128
in French
| IMEMR
| ID: emr-171781
ABSTRACT
While French authorities point to the need for rational prescribing, especially concerning psychotropic drugs, few data on the prescription of second-generation antidepressants [SGA] are synthesized for clinicians' use. Our objective is to carry out a comparative analysis of effectiveness and tolerability / acceptability of SGA. Considering the benefit/risk ratio and the cost [generic], the first-line treatment for a major depressive episode may be currently sertraline [50 mg / d]. It may however have more digestive side effects than other SSRIs [due to the serotonin action], which calls for caution while increasing doses. Fluoxetine seems relevant in treatment of negative symptoms of schizophrenia [20mg / d] and in bulimia [60 mg / d]. Fluvoxamine seems relevant in the case of sexual side effects with a previous SSRI, in treatment of anxiety disorders [it's affinity for sigma receptors may confer a specific action] and in psychotic depression. Mirtazapine may be a treatment of interest when a fast remission of depressive symptoms [especially insomnia] is warranted but its tolerance profile makes it difficult to use
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Drug Costs
/
Cost-Benefit Analysis
/
Selective Serotonin Reuptake Inhibitors
/
Drug Tolerance
Type of study:
Health economic evaluation
Limits:
Humans
Language:
French
Journal:
Tunisie Med.
Year:
2015
Similar
MEDLINE
...
LILACS
LIS